---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023808"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:52:45.451050+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q1 revenue down 58% to $4.2M; net loss $45.6M; introduces ABCL635 for hot flashes

## Summary
- Total revenue $4.2M, down 58% from $10.0M in Q1 2024.
- Net loss $45.6M ($0.15/share) vs net loss $40.6M ($0.14) year ago.
- Announces ABCL635, a first-in-class NK3R antibody for vasomotor symptoms from menopause; Phase 1 expected H2 2025.
- Available liquidity ~$810M ($633M cash + $178M government funding).
- Cumulative partner program starts 97, clinic molecules 16; R&D spend up to $42.5M.

## SEC filing metadata
- accession: 0001628280-25-023808
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/0001628280-25-023808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828025023808/abcl-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023808
- JSON: https://secwatch.observer/filing/0001628280-25-023808.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.